175 related articles for article (PubMed ID: 28988173)
1. Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Read T; Webber S; Thomas J; Wagels M; Schaider H; Soyer HP; Smithers BM
BMJ Open; 2017 Oct; 7(10):e016816. PubMed ID: 28988173
[TBL] [Abstract][Full Text] [Related]
2. [In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].
Elfatoiki FZ; Longvert C; Clerici T; Bourgault-Villada I; Roudier-Pujol C; Vasseur E; Saiag P
Ann Dermatol Venereol; 2014 Feb; 141(2):106-10. PubMed ID: 24507204
[TBL] [Abstract][Full Text] [Related]
3. Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study.
Read T; Webber S; Tan J; Wagels M; Schaider H; Soyer HP; Smithers BM
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2030-2037. PubMed ID: 28626861
[TBL] [Abstract][Full Text] [Related]
4. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
Florin V; Desmedt E; Vercambre-Darras S; Mortier L
Invest New Drugs; 2012 Aug; 30(4):1641-5. PubMed ID: 21748297
[TBL] [Abstract][Full Text] [Related]
5. Use of imiquimod for residual acral melanoma.
Sue GR; Hanlon A; Lazova R; Narayan D
BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25188932
[TBL] [Abstract][Full Text] [Related]
6. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
[TBL] [Abstract][Full Text] [Related]
7. i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
Hyatt A; Gough K; Murnane A; Au-Yeung G; Dawson T; Pearson E; Dhillon H; Sandhu S; Williams N; Paton E; Billett A; Traill A; Andersen H; Beedle V; Milne D
BMJ Open; 2020 Feb; 10(2):e036059. PubMed ID: 32114479
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
10. Topical treatment of melanoma skin metastases with imiquimod: a review.
Sisti A; Sisti G; Oranges CM
Dermatol Online J; 2015 Feb; 21(2):. PubMed ID: 25756475
[TBL] [Abstract][Full Text] [Related]
11. Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.
Veverka KK; Jakub JW; Baum CL
Dermatol Surg; 2018 Dec; 44(12):1501-1508. PubMed ID: 29985863
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.
Turza K; Dengel LT; Harris RC; Patterson JW; White K; Grosh WW; Slingluff CL
J Cutan Pathol; 2010 Jan; 37(1):94-8. PubMed ID: 19602071
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
Park AJ; Paul J; Chapman MS; Samie FH
Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708
[TBL] [Abstract][Full Text] [Related]
14. Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.
Gibbons IL; Sonagli M; Bertolli E; Macedo MP; Pinto CAL; Duprat Neto JP
An Bras Dermatol; 2018 Mar; 93(2):299-301. PubMed ID: 29723355
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
16. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
Damian DL; Shannon KF; Saw RP; Thompson JF
Australas J Dermatol; 2009 Nov; 50(4):266-71. PubMed ID: 19916970
[TBL] [Abstract][Full Text] [Related]
17. The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature.
Scarfì F; Patrizi A; Veronesi G; Lambertini M; Tartari F; Mussi M; Melotti B; Dika E
Dermatol Ther; 2020 Nov; 33(6):e14165. PubMed ID: 32772481
[TBL] [Abstract][Full Text] [Related]
18. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
[TBL] [Abstract][Full Text] [Related]
19. An Algorithm for the Management of Residual Head and Neck Melanoma In Situ Using Topical Imiquimod: A Pilot Study.
Tsay C; Kim S; Norwich-Cavanaugh A; Hsia HC; Narayan D
Ann Plast Surg; 2019 Apr; 82(4S Suppl 3):S199-S201. PubMed ID: 30855388
[TBL] [Abstract][Full Text] [Related]
20. [Topical treatment of melanoma skin metastases with imiquimod].
Sigüenza M; Pizarro A; Mayor M; Vidaurrázaga C; Miralles L; González-Beato M; Casado M
Actas Dermosifiliogr; 2005 Mar; 96(2):111-5. PubMed ID: 16476347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
